These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27502933)

  • 21. Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system.
    Yoon SE; Kim WS; Kim SJ
    Korean J Intern Med; 2020 Jul; 35(4):946-956. PubMed ID: 31752477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-adjusted EPOCH-R for Burkitt lymphoma.
    Hoelzer D
    Clin Adv Hematol Oncol; 2014 Nov; 12(11):777-9. PubMed ID: 25674718
    [No Abstract]   [Full Text] [Related]  

  • 23. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.
    Kansara R; Villa D; Gerrie AS; Klasa R; Shenkier T; Scott DW; Slack GW; Gascoyne RD; Connors JM; Sehn LH; Savage KJ
    Br J Haematol; 2017 Nov; 179(3):508-510. PubMed ID: 27443424
    [No Abstract]   [Full Text] [Related]  

  • 24. [Rituximab combined with EPOCH regimen for treatment of diffuse large B cell lymphoma of the gastrointestinal tract: analysis of 4 cases].
    Hu RH; Sun WL; Zhao H; Hui WH; Guo YX; Wan SG; Su L
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(9):1291-1294. PubMed ID: 27687667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of treatment of 112 cases of primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
    Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Demyelinating Disease; What Lies Beneath?
    Rabah F; Elmanzalawy A; Bhuyan D; El-Banna N; Beshlawi I
    Indian J Pediatr; 2016 Apr; 83(4):365-7. PubMed ID: 26204979
    [No Abstract]   [Full Text] [Related]  

  • 29. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
    Shenkier TN; Voss N; Chhanabhai M; Fairey R; Gascoyne RD; Hoskins P; Klasa R; Morris J; O'Reilly SE; Pickles T; Sehn L; Connors JM
    Cancer; 2005 Mar; 103(5):1008-17. PubMed ID: 15651059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-adjusted EPOCH-R: a feasible alternative for Burkitt lymphoma in resource-constrained settings.
    Jindal N; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
    Br J Haematol; 2020 Sep; 190(6):e362-e363. PubMed ID: 32614462
    [No Abstract]   [Full Text] [Related]  

  • 31. Omission of etoposide in the treatment of haemophagocytic lymphohistiocytosis secondary to primary central nervous system lymphoma with satisfactory response.
    Laches R; Hall RJ; Chaffin J; Hahn P
    BMJ Case Rep; 2024 Jul; 17(7):. PubMed ID: 39002953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cure in a case of primary hepatic lymphoma.
    Murthy SA; Singh B; Bhalla S; Arora A; Vohra R; Aggarwal S
    Indian J Cancer; 2000 Dec; 37(4):165-72. PubMed ID: 12018569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?
    Lakhotia R; Melani C; Roschewski M; Wilson WH
    J Clin Oncol; 2022 Jun; 40(18):2063-2064. PubMed ID: 35377729
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of progression during reductive prophase for paediatric primary mediastinal B-cell lymphoma using dose-adjusted EPOCH chemotherapy.
    Chen RL; Chuang SS; Lu YH
    Pediatr Blood Cancer; 2011 Jul; 56(7):1149-50. PubMed ID: 21337677
    [No Abstract]   [Full Text] [Related]  

  • 36. Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.
    Knörr F; Zimmermann M; Attarbaschi A; Kabíčková E; Maecker-Kolhoff B; Ruf S; Kühnle I; Ebinger M; Garthe AK; Simonitsch-Klupp I; Oschlies I; Klapper W; Burkhardt B; Woessmann W
    Haematologica; 2021 Dec; 106(12):3232-3235. PubMed ID: 34498443
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.
    Roswarski J; Roschewski M; Lucas A; Melani C; Pittaluga S; Jaffe ES; Steinberg SM; Waldmann TA; Wilson WH
    Leuk Lymphoma; 2018 Jun; 59(6):1466-1469. PubMed ID: 29032710
    [No Abstract]   [Full Text] [Related]  

  • 38. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
    Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.